Arnold D. Bullock, M.D.

Selenium and Vitamin E Chemoprevention Trial (SELECT)
This study is sponsored by the National Cancer Institute (NCI)/Southwest Oncology Group (SWOG) and will be approximately 12 years in length. This is a very large trial that has enrolled approximately 32,400 subjects across the United States. Washington University enrolled 111 subjects. The purpose of this trial is to see if supplements, selenium and Vitamin E can prevent or reduce the occurrence of prostate cancer in healthy men.

Other Ongoing Research

Funding Agency: GTx, Inc
Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for the Prevention of Bone Fractures in Men with Prostate Cancer on Androgen Deprivation Therapy

Funding Agency: Pfizer, Inc
Title: A Randomized, Double Blind, Placebo Controlled, Four Arm (Placebo, Tolterodine ER, Tamsulosin, and Tolterodine ER Plus Tamsulosin)

Study to Evaluate the Clinical Efficacy and Safety of Tolterodine ER 4 MG in Men Who Have Frequency and Urgency, With or Without Urinary Urge Incontinence, With or Without Bladder Outlet Obstruction

Dr. Arnold D. Bullock's CV